Analyzing...
Loading company...
Emcure Pharmaceuticals Ltd develops, manufactures, and markets pharmaceutical products across multiple therapeutic segments. The company emphasizes quality, regulatory compliance, and global market outreach in both branded and generic medicines.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹9,204 Cr revenue.
COGS 39.7%, employees 16.9%.
“grew 20.”
“Low to mid teens growth rate compounded is what we will aspire for...tracking slightly ahead of 13% growth guidance”
“300 to 400 basis point improvement in EBITDA margin profile over 3-5 years, roughly 100 bps improvement year on year”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 18.7%▲ | 10.3% |
| ROCE | 25.1%▲ | 13.7% |
| Net Margin | 10.0%▲ | 7.6% |
| EBITDA Margin | 20.0%▲ | 15.4% |
| Debt To Equity | 0.24x▲ | 0.15x |
| (₹ Cr) | TTM | FY2025 |
|---|---|---|
| Revenue | ₹9,204 Cr +16.6% | ₹7,896 Cr |
| Other Income | ₹13 Cr -81.2% | ₹67 Cr |
| Total Income | ₹9,216 Cr +15.7% | ₹7,963 Cr |
| COGS | ₹3,657 Cr +16.2% | ₹3,147 Cr |
| ₹7,898 Cr +13.1% | ₹6,982 Cr | |
| Profit Before Tax | ₹1,287 Cr +32.5% | ₹971 Cr |
| Exceptional Items | (₹31 Cr) -202.1% | (₹10 Cr) |
| ₹346 Cr +31.1% | ₹264 Cr | |
| Net Profit | ₹941 Cr +33.0% | ₹707 Cr |
| Profit (Owners) | ₹924 Cr +35.7% | ₹681 Cr |
| Minority Interest | ₹17 Cr -35.3% | ₹26 Cr |
| Other Comprehensive Income | ₹166 Cr +427.5% | ₹31 Cr |
| EPS | ₹48.76 | ₹35.96 |
| Diluted Shares | ₹19 Cr | ₹19 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Emcure Pharmaceuticals Limited has informed the Exchange regarding 'Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Update on completio...
Emcure Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company.
Emcure Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 20, 2026, titled "Emcure to Expand the Use of Poviztra® for MASH Indication Following CDSCO Approval".
Emcure Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Emcure Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 13, 2026, titled "Press Release titled Emcure Consolidates Gennova Ownership; Sharpens Focus on Biologics...
Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
Emcure Pharmaceuticals Limited has informed the Exchange about Sale or disposal
Revised intimation of Confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026 with correct enclosure.
Emcure Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Emcure Pharmaceuticals Limited has informed the Exchange about change in Management
Emcure Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation
Emcure Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Emcure Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Intimation of schedule of Analyst/ Investor Meeting(s) on May 27, 2026